Dysbiosis signatures of gut microbiota in coronary artery disease

Zhu, Qi; Gao, Renyuan; Zhang, Yi; Pan, Dengdeng; Zhu, Yefei; Zhang, Xiaohui; Yang, Rong; Jiang, Rong; Xu, Yawei; Qin, Huanlong

doi:10.1152/physiolgenomics.00070.2018

Cited by 152 publications

(136 citation statements)

References 44 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…The results showed that six of these genera were positively correlated with vitamin D3, including Subdoligranulum ( R 2 = 0.181, P = .0023, Figure F), Ruminiclostridium ( R 2 = 0.1217, P = .014, Figure G), Intestinimonas ( R 2 = 0.2036, P = .0011, Figure H), Pseudoflavonifractor ( R 2 = 0.1014, P = .0257, Figure I), Paenibacillus ( R 2 = 0.089, P = .0373, Figure J), and Marvinbryantia ( R 2 = 0.08173, P = .0464, Figure K). It is worth noting that Subdoligranulum is an anti‐inflammatory bacterium shown to be significantly depleted in patients with coronary artery disease . Furthermore, a previous study regarding inflammatory bowel disease (IBD), a condition in which vitamin D deficiency seems to play a role in intestinal inflammation, showed that specific gut species including Subdoligranulum were increased after oral vitamin D administration in IBD patients but not CTR.…”

Section: Resultsmentioning

confidence: 99%

Dysbiotic gut microbes may contribute to hypertension by limiting vitamin D production

Zuo

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

Background Accumulating studies have suggested that gut microbiota (GM) dysbiosis and vitamin D3 deficiency each play an important role during the progression of hypertension (HTN). However, few studies have characterized the underlying interaction between GM shift and vitamin D3 deficiency in HTN patients. Hypothesis This study aimed to evaluate the possible crosstalk between GM dysbiosis and vitamin D deficiency in the pathogenesis of HTN. Methods In a cohort of 34 HTN patients and 15 healthy controls, we analyzed the fecal microbiota products, GM composition, and the interaction between GM and vitamin D3. Results Vitamin D3 was significantly decreased in feces of HTN patients (P = .006, vs controls) and was correlated with altered GM, including decreased Shannon index (R2 = 0.1296, P = .0111) and Pielou evenness (R2 = 0.1509, P = .0058). Moreover, vitamin D3 positively correlated with HTN‐reduced bacterial genera, including Subdoligranulum (R2 = 0.181, P = .0023), Ruminiclostridium (R2 = 0.1217, P = .014), Intestinimonas (R2 = 0.2036, P = .0011), Pseudoflavonifractor (R2 = 0.1014, P = .0257), Paenibacillus (R2 = 0.089, P = .0373), and Marvinbryantia (R2 = 0.08173, P = .0464). Partial least squares structural equation modeling showed that 27.7% of the total effect of gut microbiome on HTN was mediated by limiting vitamin D production. Finally, receiver operating characteristic curve analysis revealed the predictive capacity of differential gut microbiome signatures and decreased vitamin D3 to distinguish HTN patients (AUC = 0.749, P = .006). Conclusions Our findings suggest that the GM dysbiosis contributing to the development of HTN might be partially mediated by vitamin D3 deficiency. Future studies involving the underlying mechanism and intervention strategies targeting microbiome composition and vitamin D3 to counteract the progression of HTN are warranted.

show abstract

Section: Resultsmentioning

confidence: 99%

Dysbiotic gut microbes may contribute to hypertension by limiting vitamin D production

Zuo

et al. 2019

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…A more significant finding has been the decrease of Bacteroidetes and increase of Firmicutes, Escherichia-Shigella and Enterococcus in the gut of CAD patients suggesting Figure 1. Gut microbiota may produce beneficial as well as deleterious effects in coronary artery disease patients, which is due to the production of useful or harmful metabolites that the shift in microbiota may be one of contributing factor in the development of coronary heart disease [23,24,26]. It is possible to suggest that due to alterations in the profile of gut microbiota, there are changes in the metabolism in the gut and subsequently, altered metabolic products may gain entry in the blood circulation to produce deleterious effects.…”

Section: Discussionmentioning

confidence: 99%

“…Other bacterial species that were relatively less represented in the gut of CAD patients included Subdoligranulum, Roseburia, and Eubacterium rectale. It further signifies that gut microbiota dysbiosis is an important risk factor for the development of CAD and identification of changes in its composition may be potentially employed for its diagnosis [26].…”

Section: Gut Microbiota Composition and Its Possible Use As A Non-invmentioning

confidence: 99%

Gut microbiota in coronary artery disease: a friend or foe?

et al. 2020

View full text Add to dashboard Cite

There is a growing interest in the role of gut microbiota in the pathophysiology of several diseases, including coronary artery diseases (CAD). Gut microorganisms may produce beneficial effects in myocardial ischemia either directly in the form of exogenous administration or indirectly by acting on fiber-rich food to produce important cardioprotective components. The harmful effects of gut microbiota in CAD are due to alteration in their composition with a significant decrease in Bacteroidetes and an increase in Firmicutes, Escherichia, Shigella, and Enterococcus. The altered microbiota may produce potentially toxic metabolites, including trimethylamine-N-oxide (TMAO). Indeed, the fasting plasma levels of TMAO are directly correlated to increased risk of major cardiovascular events in CAD patients, and it is proposed as a potential biomarker to predict the onset of major cardiovascular events. It is concluded that the change in the composition of gut microbiota in CAD patients may predispose to more harmful effects. However, exogenous delivery of probiotics may overcome the detrimental effects of myocardial ischemia.

show abstract

“…[41] Regarding the speci c taxonomy of the gut microbiome, the genus Flavonifractor was enriched in βblocker users in both the full and PS-matched cohorts. Flavonifractor is associated with several diseases, such as obesity, [42] atrial brillation, [43] coronary artery disease, [44] major depressive disorder, [45] and bipolar disorder [46], and medications (antidiabetic drugs, such as Metformin and Glucagon-like peptide 1…”

Section: Discussionmentioning

confidence: 99%

“…It can convert quercetin or other avonoids into acetic acid and butyric acid [48] and is also correlated with oxidative stress and in ammation. [46] Taken together, Flavonifractor is signi cantly less abundant in the subjects with obesity, [42] atrial brillation, [43] or coronary artery disease, [44] thus, the increased abundance of Flavonifractor by β-blocker treatment may have a potential bene t in cardiovascular disease via gut microbiota regulation. However, an enriched Flavonifractor in major depressive disorder [45] and bipolar disorder [46] could also link the relationship between β-blockers and major depressive disorder or bipolar disorder.…”

Section: Discussionmentioning

confidence: 99%

Differences in the Microbial Composition of Hemodialysis Patients Treated With and Without β-Blockers

Lin

Hung

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: β-blockers are commonly prescribed medications to treat cardiovascular disease and prevent sudden cardiac death during hemodialysis. Beyond the medication effects on the host, no study has investigated the impact of β-blocker on the gut microbiota in hemodialysis patients. Results: The β-blocker users had a higher proportion of diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, heart failure, cerebrovascular disease, and concurrent medications than non-users. After propensity score (PS) matching, there were no differences in comorbidities and concomitant medications. The α-diversity (Simpson index) increased in β-blocker users with a distinct β-diversity (Bray-Curtis Index) compared to non-users in the full cohort and PS-matched cohort. In the linear discriminative analysis effect size analysis and zero-inflated Gaussian fit model, there was a significant enrichment in the genus Flavonifractor in β-blocker users compared to non-users in the full cohort and PS-matched cohort; this was confirmed by random forest analysis. Conclusions: Hemodialysis patients using β-blocker used had a different gut microbiota composition compared to non-users, in particular, the Flavonifractor genus was significantly increased with β-blocker treatment. These findings highlight the significant impact of β-blockers on the gut microbiome in hemodialysis patients. Further research is warranted regarding the mechanisms and their clinical consequences.

show abstract

Dysbiosis signatures of gut microbiota in coronary artery disease

Cited by 152 publications

References 44 publications

Dysbiotic gut microbes may contribute to hypertension by limiting vitamin D production

Dysbiotic gut microbes may contribute to hypertension by limiting vitamin D production

Gut microbiota in coronary artery disease: a friend or foe?

Differences in the Microbial Composition of Hemodialysis Patients Treated With and Without β-Blockers

Contact Info

Product

Resources

About